Sutter Health Research Enterprise
2340 Clay Street
San Francisco, CA, 94115
(415) 600-1020
ClinicalResearch@sutterhealth.org
Sutter Health Research Enterprise
2340 Clay Street
San Francisco, CA, 94115
(415) 600-1020
ClinicalResearch@sutterhealth.org
Related Clinical Trials
ASSURE
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)
Investigators: Edward Holt MD, Raphael Merriman MD, Kidist Yimam MD
Status: Active, Recruiting
Eiger Hepatitis D Study
Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV (LIMT-2)
Investigators: Stewart Cooper M.D., Raphael Merriman MD, Kidist Yimam MD
Status: Active, Recruiting
ELATIVE
Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) (ELATIVE)
Investigators: Edward Holt MD, Raphael Merriman MD, Kidist Yimam MD
Status: Active, Recruiting
InFUSE
Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE)
Investigators: Todd Frederick M.D., Edward Holt MD, Raphael Merriman MD
Status: Active, Recruiting
MIRUM
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) (VIST
Investigators: Edward Holt MD, Raphael Merriman MD, Kidist Yimam MD
Status: Active, Recruiting
NATIV3
A Phase 3 Study Evaluating Long-term Efficacy and Safety of Lanifibranor in Adult Patients With (NASH) and Fibrosis 2 (F2)/Fibrosis 3 (F3) Stage of Liver Fibros
Investigator: Raphael Merriman MD
Status: Active, Recruiting
RESPONSE
RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA
Investigators: Edward Holt MD, Raphael Merriman MD, Kidist Yimam MD
Status: Active, Recruiting